Oncology References
REFERENCES IN CHRONOLOGICAL ORDER |
(Updated on June 3, 2010) |
Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M. (2010) Serum M30 levels are associated with survival in advanced gastric carcinoma patients.
Int Immunopharmacol. 2010 Mar 31
»Abstract
Linder S, Olofsson MH, Herrmann R, Ulukaya E. (2010)
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
Exp Rev Mol Diagn 10: 353-9.
»Abstract
Dive C, Smith RA, Garner E, Ward T, George-Smith SS, Campbell F, Greenhalf W, Ghaneh P, Neoptolemos JP. (2010)
Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.
Br J Cancer 102:577-82.
»Abstract
Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R, Peach ML, Juan G, Kaufman S, Chen Q, Bianchi A, Kordich JJ, Ma M, Foltz IN, Gliniak BC. (2010)
Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types.
Cancer Biol. Ther. 9., EPub
»Abstract
2009
Ausch C, Buxhofer-Ausch V, Olszewski U, Schiessel R, Ogris E, Hinterberger W, Hamilton G. (2009)
Circulating Cytokeratin 18 Fragment M65-A Potential Marker of Malignancy in Colorectal Cancer Patients.
J Gastrointest Surg. 2009 Sep 2.
»Abstract
Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, Hamilton G. (2009)
Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.
Eur J Surg Oncol. 2009 Feb 28. [Epub ahead of print]
»AbstractBerndtsson M, Hernlund E, Shoshan MC, Linder S. (2009)
Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.
J Chem Biol. 2009 Jun;2(2):81-7.
»Abstract
Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek FJ. (2009)
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
Mol Cancer Ther. 2009 Aug;8(8):2122-30.
»Abstract
Fayad W, Fryknäs M, Brnjic S, Olofsson MH, Larsson R, Linder S. (2009)
Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters.
PLoS ONE 4(10): e7238.
»Abstract
Fayad W, Brnjic S, Berglind D, Blixt S, Shoshan MC, Berndtsson M, Olofsson MH, Linder S. (2009)
Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model.
Int J Cancer 15: 2450-5.
»Abstract
Fisher MB, Zhang XQ, McConkey DJ, Benedict WF. (2009)
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.
Cancer Gene Ther. 2009 Feb 6. [Epub ahead of print]
»Abstract
Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, Eksborg S, Arnér ES, Shoshan M, Ehrsson H, Laurell G. (2009)
Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.
J Natl Cancer Inst. 2009 Jan 7;101(1):37-47. Epub 2008 Dec 30.
»Abstract
Hernlund E, Kutuk O, Basaga H, Linder S, Panaretakis T, Shoshan M. (2009)
Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation.
Free Radic Biol Med. 2009 Jun 15;46(12):1607-13.
»Abstract
Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. (2009)
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
Am J Pathol. 2009 Aug;175(2):808-16.
»Abstract
Kieback DG. (2009)
Adenovirus-mediated thymidine kinase gene therapy induces apoptosis in human epithelial ovarian cancer cells and damages PARP-1.
In Vivo. 2009 Jan-Feb;23(1):77-80
»Abstract
Koelink PJ, Lamers CB, Hommes DW, Verspaget HW. (2009)
Circulating cell death products predict clinical outcome of colorectal cancer patients.
BMC Cancer. 2009 Mar 23;9:88.
»Abstract
Koelink PJ, Sier CF, Hommes DW, Lamers CB, Verspaget HW. (2009)
Clinical significance of stromal apoptosis in colorectal cancer.
Br J Cancer. 101:765-73.
»Abstract
Kutuk O, Arisan ED, Tezil T, Shoshan MC, Basaga H. (2009)
Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation.
Carcinogenesis. 2009 Sep;30(9):1517-27.
»Abstract
Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, Rundlöf AK, Fernandes AP, Björnstedt M, Dobra K. (2009)
Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.
Journal of Experimental & Clinical Cancer Research 2009, 28:92
»Abstract
Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S. (2009)
Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.
Cancer Biomark. 2009;5(3):117-25.
»Abstract
Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. (2009)
Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Int Immunopharmacol. 2009 Feb 26. [Epub ahead of print]
»Abstract
Pfeifer D, Wallin A, Holmlund B, Sun XF. (2009)
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells.
J Cancer Res Clin Oncol. 2009 Nov;135(11):1583-92.
»Abstract
Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R. (2009)
Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
Br J Cancer. 2009 Aug 4;101(3):410-7.
»Abstract
Schutte B, Henfling ME, Verheyen FK, Li G, Tolstonog GV, Ramaekers FC. (2009)
The caspase-9 derived C-terminal fragment of cytokeratin 18 modulates topoisomerase action.
Int J Oncol. 35:625-30.
»Abstract
Ullen A, Schwarz S, Lennartsson L, Kalkner KM, Sandstrom P, Costa F, Lennernas B, Linder S, Nilsson S. (2009)
Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.
Scand J Urol Nephrol. 2009;43(2):98-103.
»Abstract
2008
Beachy SH, Repasky EA. (2008)
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update.
Cancer Immunol Immunother. 2008 Jun;57(6):759‑75. Epub 2008 Jan 10.
»Abstract
Carpinelli P, Moll J. (2008)
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
Expert Opin Ther Targets. 2008 Jan;12(1):69‑80.
»Abstract
Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, Ward TH,
Wilkinson RW, Growcott J, Hughes A, Dive C. (2008)
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Mol Cancer Ther. 2008 Mar;7(3):455‑63.
»Abstract
Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. (2008)
Biomarker method validation in anticancer drug development.
Br J Pharmacol. 2008 Feb;153(4):646‑56. Epub 2007 Sep 17.
»Abstract
de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA. (2008)
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug‑sensitive tumor, testicular cancer.
Neoplasia. 2008 Oct;10(10):1041‑8.
»Abstract
Friedman J, Dunn RL, Wood D, Vaishampayan U, Wu A, Bradley D, Montie J, Sarkar FH, Shah RB, Hussain M. (2008)
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
J Urol. 2008 Mar;179(3):911‑5; discussion 915‑6. Epub 2008 Jan 22. Links
»Abstract
Greystoke A., Cummings J., Ward T., Simpson K., Renehan A., Butt F., Moore D., Gietema J., Blackhall F., Ranson M., Hughes A., Dive C. (2008)
Optimisation of circulating biomarkers of cell death for routine clinical use.
Ann Oncol. 2008 Feb 27 [Epub ahead of print]
»Abstract
Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, Shoshan MC. (2008)
Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir.
Int J Cancer. 2008 Jul 15;123(2):476-83.
»Abstract
Herrmann R, Fayad W, Schwarz S, Berndtsson M, Linder S. (2008)
Screening for Compounds that Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids.
J Biomol Screen. 2008 Feb;13(1):1‑8. (Epub 2007 Nov 26.)
»Abstract
Ihrlund Strandberg L, Hernlund E, Khan O and Shoshan M C. (2008)
3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.
Molecular Oncology Volume 2, Issue 1, June 2008, Pages 94-101
»Abstract
Panaretakis T, Hjortsberg L, Tamm KP, Björklund AC, Joseph B, Grandér D. (2008)
Interferon alpha induces nucleus‑independent apoptosis by activating extracellular signal‑regulated kinase 1/2 and c‑Jun NH2‑terminal kinase downstream of phosphatidylinositol 3‑kinase and mammalian target of rapamycin.
Mol Biol Cell. 2008 Jan;19(1):41‑50. Epub 2007 Oct 17.
»Abstract
Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis EK, Archimandritis AJ. (2008)
Serum apoptotic caspase activity as a marker of severity in HBeAg‑negative chronic hepatitis B virus infection.
Gut. 2008 Apr;57(4):500‑6. Epub 2007 Nov 19.
»Abstract
Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl‑Jensen P, Brown R, Evans TR, DeBono JS. (2008)
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Clin Cancer Res. 2008 Feb 1;14(3):804‑10.
»Abstract
2007
Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. (2007)
Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA.
Int J Cancer. 2007 Jan 1;120(1):175‑80.
»Abstract
Cummings J, Ranson M, Butt F, Moore D, Dive C. (2007)
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
Cancer Chemother Pharmacol. 2007 Feb 27;
»Abstract
Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. (2007)
Biomarker method validation in anticancer drug development.
Br J Pharmacol. 2007 Sep 17;1‑11
»Abstract
Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV. (2007)
8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Mol Pharmacol. 2007 Nov;72(5):1137-45. Epub 2007 Aug 3.
»Abstract
Jacob DA, Bahra M, Langrehr JM, Boas‑Knoop S, Stefaniak R, Davis J, Schumacher G, Lippert S, Neumann UP. (2007)
Combination therapy of poly (ADP‑ribose) polymerase inhibitor 3‑aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
J Gastroenterol Hepatol. 2007 May;22(5):738‑48.
»Abstract
Jackson CL, Dreaden TM, Theobald LK, Tran NM, Beal TL, Eid M, Gao MY, Shirley RB, Stoffel MT, Vijay Kumar M, Mohnen D. (2007)
Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure.
Glycobiology. 2007 May 19;
»Abstract
Linder, S. (2007)
Cytokeratin Markers Come of Age.
Tumour Biol. 2007 Aug 23;28(4):189‑195
»Abstract
Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S. (2007)
Cytokeratin‑18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.
Clin Cancer Res. 2007 Jun 1;13(11):3198‑206.
»Abstract
Papatheodoridis GV, Hadizyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis E, Archimandritis AJ. (2007)
Serum Apoptotic Caspase Activity As A Marker Of Severity In Hbeag‑Negative Chronic Hepatitis B Virus Infection.
Gut. 2007 Nov 19 [Epub ahead of print]
»Abstract
Rutherford AE, Hynan LS, Borges CB, Forcione DG, Blackard JT, Lin W, Gorman AR, Shaikh OS, Reuben A, Harrison E, Reddy KR, Le WM, Chung RT; For the alf study group. (2007)
Serum Apoptosis Markers in Acute Liver Failure: A Pilot Study.
Clin Gastroenterol Hepatol. 2007;5:1477‑1483
»Abstract
Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. (2007)
The levels of caspase‑cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
Lung Cancer. 2007 Feb 19;
»Abstract
2006
Cummings J, Ranson M, Lacasse E, Ganganagari JR, St‑Jean M, Jayson G, Durkin J, Dive C. (2006)
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X‑linked inhibitor of apoptosis protein XIAP.
Br J Cancer. 2006 Jul 3;95(1):42‑8.
»Abstract
Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T, Manavoglu O. (2006)
Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase‑Cleaved Cytokeratin 18: A Prospective Pilot Study.
Cancer Invest. 2006 Nov;24(7):669‑76.
»Abstract
Duan Z, Bradner JE, Greenberg E, Levine R, Foster R, Mahoney J and Seiden MV. (2006)
SD‑1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Clin Cancer Res. 2006 Nov 15;12(22):6844‑52.
»Abstract
Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV. (2006)
Signal transducers and activators of transcription 3 pathway activation in drug‑resistant ovarian cancer.
Clin Cancer Res. 2006 Sep 1;12(17):5055‑63.
»Abstract
Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF. (2006)
Diarylureas are small‑molecule inhibitors of insulin‑like growth factor I receptor signaling and breast cancer cell growth.
Mol Cancer Ther. 2006 Apr;5(4):1079‑86.
»Abstract
Kaddour‑Djebbar I, Lakshmikanthan V, Shirley RB, Ma Y, Lewis RW, Kumar MV. (2006)
Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer.
Mol Cancer Ther. 2006 Aug;5(8):1958‑66.
»Abstract
Kramer, G., Schwartz, S., Hägg, M., Mandic Havelka, A. and Linder, S. (2006)
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
Br J Cancer. 2006 Jun 5;94(11):1592‑8.
»Abstract
Lakshmikanthan V, Kaddour‑Djebbar I, Lewis RW, Kumar MV. (2006)
SAHA‑sensitized prostate cancer cells to TNFalpha‑related apoptosis‑inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
Int J Cancer. 2006 Jul 1;119(1):221‑8.
»Abstract
Leuhuber K, Klepal W, Hausott B, Marian B. (2006)
Apoptosis in a tissue‑like culture model of human colorectal adenoma cells.
Tissue Cell. 2006 Jun;38(3):203‑8.
»Abstract
Ma, Y., Lakshmikanthan, V., Lewis, R.W. and Kumar, M.V. (2006)
Sensitization of TRAIL‑restistant cells by inhibition of heat shock protein 90 with low‑dose geldanamycin.
Mol Cancer Ther. 2006 Jan;5(1):170‑8.
»Abstract
Pichon MF, Labroquere M, Rezai K, Lokiec F. (2006)
Variations of soluble fas and cytokeratin 18‑Asp 396 neo‑epitope in different cancers during chemotherapy.
Anticancer Res. 2006 May‑Jun;26(3B):2387‑92.
»Abstract
Shoshan M, Mandic Havelka A, Neumann F and Linder S. (2006)
Sense and sensibility: the use of cell death biomarker assays in high‑throughput anticancer drug screening and monitoring treatment responses.
Expert Opin. Drug Discov. 2006 Nov; Vol. 1, No. 6: 585‑594.
»Abstract
Shukla, S. and Gupta, S. (2006)
Molecular targets for apigenin‑induced cell cycle arrest and apoptosis in prostate cancer cell xenograft.
Mol Cancer Ther. 2006 Apr;5(4):843‑52.
»Abstract
Welman A, Cawthorne C, Ponce-Perez L, Barraclough J, Danson S, Murray S, Cummings J, Allen TD, Dive C. (2006)
Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo.
Neoplasia. 2006 Nov;8(11):905-16.
»Abstract
2005
Berndtsson M, Konishi Y, Bonni A, Hagg M, Shoshan M, Linder S, Havelka AM. (2005)
Phosphorylation of BAD at Ser‑128 during mitosis and paclitaxel‑induced apoptosis.
FEBS Lett. 2005 Jun 6;579(14):3090‑4.
»Abstract
Cummings J, Ward TH, Lacasse E, Lefebvre C, St‑Jean M, Durkin J, Ranson M and Dive C. (2005)
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X‑linked inhibitor of apoptosis protein XIAP.
Br J Cancer. 2005 Feb 14;92(3):532‑8.
»Abstract
Erdal, H., Berndtsson, M., Castro, J., Brunk, U., Shoshan, M.C. and Linder, S. (2005)
Induction of lysosomal membrane permeabilization by compounds that activate p53‑independent apoptosis.
Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):192‑7. Epub 2004 Dec 23
»Abstract
Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, Mantovani G, Cellai I, Ammannati F, Spada A, Serio M, Peri A. (2005)
Expression of the antiapoptotic gene seladin‑1 and octreotide‑induced apoptosis in growth hormone‑secreting and nonfunctioning pituitary adenomas.
J Clin Endocrinol Metab. 2005 Nov;90(11):6156‑61. Epub 2005 Aug 9.
»Abstract
Lövborg, H., Gullbo, J. and Larsson, R (2005)
Screening for apoptosis ‑ classical and emerging techniques (Review paper)
Anticancer Drugs. 2005 Jul;16(6):593‑9.
»Abstract
Shirley, B.S., Kaddour‑Djebbar, I., Patel, D.M., Lakshmikanthan, V., Lewis, R.W. and Kumar, M.V. (2005)
Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells.
Neoplasia. 2005 Dec;7(12):1104‑11.
»Abstract
Ueno, T., Toi, M. and Linder, S. (2005)
Detection of epithelial cell death in the body by cytokeatin 18 measurement.
Biomed&Pharmacotherapy 2005 Oct, 359‑362.
»Abstract
2004
Amantana A, London CA, Iversen PL, Devi GR. (2004)
X‑linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells.
Mol Cancer Ther. 2004 Jun;3(6):699‑707.
»Abstract
Cummings J, Ward TH, Ranson M, Dive C. (2004)
Apoptosis pathway‑targeted drugs ‑ from the bench to the clinic.
Biochim Biophys Acta. 2004 Dec 10;1705(1):53‑66.
»Abstract
Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. (2004)
Cimicifuga racemosa extract inhibits proliferation of estrogen receptor‑positive and negative human breast carcinoma cell lines by induction of apoptosis.
Breast Cancer Res Treat. 2004 Mar;84(2):151‑60.
»Abstract
Hägg, M., Berndtsson, M., Mandic, A., Zhou, R., Shoshan, M.C., and Linder, S. (2004)
Induction of ER stress by Ellipticine Plant Alkaloids.
Mol Cancer Ther. 2004 Apr;3(4):489‑97.
»Abstract
Kramer, G., Erdal, H., Mertens, H., Nap, M., Mauermann, J., Steiner, G., Marberger, M., Bivén, K., Shoshan, M.C. and Linder, S. (2004)
Differentiation between Cell Death Modes using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18.
Cancer Res. 2004 Mar 1;64(5):1751‑6.
»Abstract
Linder S, Havelka AM, Ueno T, Shoshan MC. (2004)
Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker.
Cancer Lett. 2004 Oct 8;214(1):1‑9.
»Abstract
Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
Journal of Urology 2004 Apr;171(4):1688‑97.
»Abstract
Muhl H, Paulukat J, Hofler S, Hellmuth M, Franzen R, Pfeilschifter J. (2004)
The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase‑1 in DLD‑1 colon carcinoma cells.
Br J Pharmacol. 2004 Dec;143(7):890‑8. Epub 2004 Oct 25.
»Abstract
Takada M, Kataoka A, Toi M, Bando H, Toyama K, Horiguchi S, Ueno T, Linder S, Saji S, Hayashi Y, Funata N, Kinoshita J, Murakami S, Ohono S. (2004)
A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer.
Int J Oncol. 2004 Aug;25(2):397‑405.
»Abstract
2003
Bivén, K., Erdal, H., Hägg, M., Ueno, T., Zhou, R., Lynch, M., Rowley, B., Wood, J., Zhang, C., Toi, M., Shoshan, M.C. and Linder, S. (2003)
A novel assay for discovery and characterization of pro‑apoptotic drugs and for monitoring apoptosis in patient sera.
Apoptosis. 2003 Jun;8(3):263‑8.
»Abstract
Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM,
Blattler WA, Chittenden T, Singh R. (2003)
An anti‑insulin‑like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
Cancer Res. 2003 Aug 15;63(16):5073‑83.
»Abstract
Thurnher, D., Turhani, D., Pelzmann, M., Wannemacher, B., Knerer, B., Formanek, M., Wacheck, V. and Selzer, E. (2003)
Betulinic Acid: A new cytotoxic compound against malignant head & neck cancer cells.
Head Neck. 2003 Sep;25(9):732‑40.
»Abstract
Ueno, T., Toi, M., Bivén, K., Bando, H., Ogawa, T. and Linder, S. (2003)
Measurement of an apoptosis product in the sera of breast cancer patients.
Eur J Cancer. 2003 Apr;39(6):769‑74.
»Abstract
2002
Hägg, M., Bivén, K., Ueno, T., Rydlander, L, Björklund, P., Wiman, K.G., Shoshan, M.C. and Linder, S. (2002)
A novel high‑through‑put assay for screening of pro‑apoptotic drugs.
Invest New Drugs. 2002 Aug;20(3):253‑9.
»Abstract
2001
Mandic, A., Viktorsson, K., Molin, M., Akusjärvi, G., Eguchi, H., Hayashi, S.‑I., Toi, M., Hansson, J., Linder, S. and Shoshan, M. (2001)
Cisplatin induces the pro‑apoptotic conformation of Bak in a delta‑MEKK1‑dependent manner.
Mol Cell Biol. 2001 Jun;21(11):3684‑91.
»Abstract
